Identifiable Intangible Assets and Goodwill (Tables)

9 Months Ended

Sep. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets

The following table provides the components of Identifiable intangible assets:
	September 30, 2018							December 31, 2017
(MILLIONS OF DOLLARS)	Gross Carrying Amount		Accumulated Amortization			Identifiable Intangible Assets, less Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization			Identifiable Intangible Assets, less Accumulated Amortization
Finite-lived intangible assets
Developed technology rights(a)	$	92,123	$	(57,786	)	$	34,337	$	89,550	$	(54,785	)	$	34,765
Brands	2,126		(1,228		)	898		2,134		(1,152		)	982
Licensing agreements and other	1,938		(1,160		)	777		1,911		(1,096		)	815
	96,187		(60,175		)	36,012		93,595		(57,033		)	36,562
Indefinite-lived intangible assets
Brands and other	6,909					6,909		6,929					6,929
IPR&D(a)	2,385					2,385		5,249					5,249
	9,294					9,294		12,179					12,179
Identifiable intangible assets(b)	$	105,481	$	(60,175	)	$	45,306	$	105,774	$	(57,033	)	$	48,741

^(a)  The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $2.7 billion from IPR&D to Developed technology rights to reflect the approval of Xtandi in the U.S. for the treatment of men with non-metastatic castration-resistant prostate cancer, which is being developed through a collaboration with Astellas, and (ii) $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E).

^(b)    The decrease in Identifiable intangible assets, less accumulated amortization, is primarily due to amortization, partially offset by additions, mainly consisting of $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E).

Schedule of Indefinite Lived Intangible Assets

The following table provides the components of Identifiable intangible assets:
	September 30, 2018							December 31, 2017
(MILLIONS OF DOLLARS)	Gross Carrying Amount		Accumulated Amortization			Identifiable Intangible Assets, less Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization			Identifiable Intangible Assets, less Accumulated Amortization
Finite-lived intangible assets
Developed technology rights(a)	$	92,123	$	(57,786	)	$	34,337	$	89,550	$	(54,785	)	$	34,765
Brands	2,126		(1,228		)	898		2,134		(1,152		)	982
Licensing agreements and other	1,938		(1,160		)	777		1,911		(1,096		)	815
	96,187		(60,175		)	36,012		93,595		(57,033		)	36,562
Indefinite-lived intangible assets
Brands and other	6,909					6,909		6,929					6,929
IPR&D(a)	2,385					2,385		5,249					5,249
	9,294					9,294		12,179					12,179
Identifiable intangible assets(b)	$	105,481	$	(60,175	)	$	45,306	$	105,774	$	(57,033	)	$	48,741

^(a)  The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $2.7 billion from IPR&D to Developed technology rights to reflect the approval of Xtandi in the U.S. for the treatment of men with non-metastatic castration-resistant prostate cancer, which is being developed through a collaboration with Astellas, and (ii) $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E).

^(b)    The decrease in Identifiable intangible assets, less accumulated amortization, is primarily due to amortization, partially offset by additions, mainly consisting of $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E).

Identifiable Intangible Assets as a Percentage of Total Identifiable Intangible Assets Less Accumulated Amortization, By Segment

Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:
	September 30, 2018
	IH		EH		WRD
Developed technology rights	70	%	29	%	—
Brands, finite-lived	75	%	25	%	—
Brands, indefinite-lived	71	%	29	%	—
IPR&D	64	%	21	%	15	%

Schedule of Goodwill

The following table provides the components of and changes in the carrying amount of Goodwill:
(MILLIONS OF DOLLARS)	IH			EH			Total
Balance, December 31, 2017	$	31,141		$	24,811		$	55,952
Other(a)	(178		)	(160		)	(338		)
Balance, September 30, 2018	$	30,964		$	24,651		$	55,614

^(a)  Primarily reflects the impact of foreign exchange, as well as the contribution of the allogeneic CAR T developmental program assets and operations to Allogene that constituted a business for accounting purposes (see Note 2B).